To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Registration Number
- NCT00143338
- Lead Sponsor
- Pfizer
- Brief Summary
To examine the lung when people with diabetes take an inhaled form of insulin, compared to subcutaneous insulin.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Type 2 Diabetes Mellitus
- Normal lung function
Exclusion Criteria
- Smokers
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To assess in patients with type 2 diabetes mellitus the effects, if any, on lung lining fluid cell count and differential within subjects after 12 weeks of inhaled insulin therapy compared to 12 weeks of subcutaneous short-acting therapy.
- Secondary Outcome Measures
Name Time Method (1) Albumin and fibrinogen concentrations, and airway appearance in the above subjects. (2) routine safety, tolerance, and efficacy in the above subjects.
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇺🇸San Antonio, Texas, United States